Premier Alternatives

BigHat Biosciences

San Mateo, CA · Founded 2019 · Privately Held (backing)

Developer of an experimental antibody platform designed to empower biological antibodies and other therapeutic proteins. BigHat Biosciences is based in San Mateo, CA and was founded in 2019. It was valued at $332 million at its later-stage round in Apr 2025, the last priced event on record. It has raised $148 million across 3 recorded rounds; the latest was a $124 million later-stage round in Jun 2022.

PMV mark · valuation
$332.0M
Oct 2026
Priced at
its later-stage round
Apr 2025
Total raised
$148.3M
Last round
Later Stage VC
Jun 2022

BigHat Biosciences key facts

as of Oct 2026
  • Developer of an experimental antibody platform designed to empower biological antibodies and other therapeutic proteins.
  • BigHat Biosciences is valued at approximately $332.0M as of Oct 2026, set at its later-stage round, Apr 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $148.3M across 3 recorded rounds; the latest was Later Stage VC ($124.1M) in Jun 2022.
  • Notable investors include Andreessen Horowitz, Gaingels, 8VC, Samsung Venture Investment, Kevin Moore — 25 tracked in total.
  • BigHat Biosciences has filed 4 Form Ds with the SEC since 2019, most recently Apr 2025 ($124.1M sold to 40 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$332.0M

Valued at $332.0M at its later-stage round, Apr 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of BigHat Biosciences with a free account
  • ·The complete investor list: 25 names
  • ·Watch BigHat Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BigHat Biosciences funding rounds

3 rounds
Jun 2022Later Stage VC$124.1MSEC filing▮
Jan 2021Early Stage VC$18.8MSEC filing▮
Oct 2019Early Stage VC$5.3MSEC filing▮
Full funding history →

BigHat Biosciences valuation

BigHat Biosciences was valued at $332 million at its later-stage round in Apr 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has BigHat Biosciences raised?

BigHat Biosciences has raised $148 million across 3 recorded rounds since 2019. The largest was a $5.3 million early-stage round in Oct 2019; the most recent was a $124 million later-stage round in Jun 2022.

BigHat Biosciences has filed 4 Form Ds with the SEC since 2019, most recently in Apr 2025 ($124 million sold to 40 investors).

BigHat Biosciences investors

25 investors are on record for BigHat Biosciences, including Andreessen Horowitz, Gaingels, 8VC and Samsung Venture Investment. By type, the record holds 9 venture capital firms and 1 angel investor. The later-stage round in Jun 2022 drew 40 investors.

About BigHat Biosciences

Developer of an experimental antibody platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.

Sector
Healthcare
HQ
San Mateo, CA, United States
Founded
2019
Employees
99
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.